268 related articles for article (PubMed ID: 21693624)
1. Mechanism of the anti-proliferative action of 25-hydroxy-19-nor-vitamin D(3) in human prostate cells.
Munetsuna E; Nakabayashi S; Kawanami R; Yasuda K; Ohta M; Arai MA; Kittaka A; Chen TC; Kamakura M; Ikushiro S; Sakaki T
J Mol Endocrinol; 2011 Oct; 47(2):209-18. PubMed ID: 21693624
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and Action of 25-Hydroxy-19-nor-Vitamin D₃ in Human Prostate Cells.
Munetsuna E; Kittaka A; Chen TC; Sakaki T
Vitam Horm; 2016; 100():357-77. PubMed ID: 26827959
[TBL] [Abstract][Full Text] [Related]
4. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
[TBL] [Abstract][Full Text] [Related]
5. Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1.
Urushino N; Nakabayashi S; Arai MA; Kittaka A; Chen TC; Yamamoto K; Hayashi K; Kato S; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Drug Metab Dispos; 2007 Sep; 35(9):1482-8. PubMed ID: 17553915
[TBL] [Abstract][Full Text] [Related]
6. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
7. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
8. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
Iglesias-Gato D; Zheng S; Flanagan JN; Jiang L; Kittaka A; Sakaki T; Yamamoto K; Itoh T; Lebrasseur NK; Norstedt G; Chen TC
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):269-75. PubMed ID: 21911059
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol.
Diesel B; Radermacher J; Bureik M; Bernhardt R; Seifert M; Reichrath J; Fischer U; Meese E
Clin Cancer Res; 2005 Aug; 11(15):5370-80. PubMed ID: 16061850
[TBL] [Abstract][Full Text] [Related]
10. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
11. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
Bareis P; Kállay E; Bischof MG; Bises G; Hofer H; Pötzi C; Manhardt T; Bland R; Cross HS
Exp Cell Res; 2002 Jun; 276(2):320-7. PubMed ID: 12027461
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of vitamin D3 by cytochromes P450.
Sakaki T; Kagawa N; Yamamoto K; Inouye K
Front Biosci; 2005 Jan; 10():119-34. PubMed ID: 15574355
[TBL] [Abstract][Full Text] [Related]
13. 1alpha,25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells.
Lechner D; Kállay E; Cross HS
Mol Cell Endocrinol; 2007 Jan; 263(1-2):55-64. PubMed ID: 17029768
[TBL] [Abstract][Full Text] [Related]
14. The role of Vitamin D3 metabolism in prostate cancer.
Lou YR; Qiao S; Talonpoika R; Syvälä H; Tuohimaa P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):317-25. PubMed ID: 15663995
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Vitamin D hydroxylases gene expression by 1,25-dihydroxyvitamin D3 and cyclic AMP in cultured human syncytiotrophoblasts.
Avila E; Díaz L; Barrera D; Halhali A; Méndez I; González L; Zuegel U; Steinmeyer A; Larrea F
J Steroid Biochem Mol Biol; 2007 Jan; 103(1):90-6. PubMed ID: 17079137
[TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
17. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor.
Harant H; Spinner D; Reddy GS; Lindley IJ
J Cell Biochem; 2000 Apr; 78(1):112-20. PubMed ID: 10797570
[TBL] [Abstract][Full Text] [Related]
18. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand.
Lou YR; Molnár F; Peräkylä M; Qiao S; Kalueff AV; St-Arnaud R; Carlberg C; Tuohimaa P
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):162-70. PubMed ID: 19944755
[TBL] [Abstract][Full Text] [Related]
19. Human cytochrome P450-dependent differential metabolism among three 2α-substituted-1α,25-dihydroxyvitamin D(3) analogs.
Yasuda K; Ikushiro S; Kamakura M; Takano M; Saito N; Kittaka A; Chen TC; Ohta M; Sakaki T
J Steroid Biochem Mol Biol; 2013 Jan; 133():84-92. PubMed ID: 22982757
[TBL] [Abstract][Full Text] [Related]
20. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer.
Murillo G; Matusiak D; Benya RV; Mehta RG
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):763-7. PubMed ID: 17257827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
